Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Equity Ratio: 2015-2020

Historic Equity Ratio for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to 0.36.

  • Outlook Therapeutics' Equity Ratio rose 283.70% to 0.36 in Q2 2020 from the same period last year, while for Jun 2020 it was 0.36, marking a year-over-year increase of 283.70%. This contributed to the annual value of -0.94 for FY2019, which is 17.89% up from last year.
  • As of Q2 2020, Outlook Therapeutics' Equity Ratio stood at 0.36, which was up 123.27% from -1.56 recorded in Q1 2020.
  • Outlook Therapeutics' Equity Ratio's 5-year high stood at 0.36 during Q2 2020, with a 5-year trough of -2.97 in Q4 2019.
  • Its 3-year average for Equity Ratio is -1.11, with a median of -1.18 in 2018.
  • Per our database at Business Quant, Outlook Therapeutics' Equity Ratio slumped by 3,666.61% in 2017 and then surged by 283.70% in 2020.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Equity Ratio stood at -1.07 in 2016, then increased by 27.20% to -0.78 in 2017, then crashed by 81.22% to -1.41 in 2018, then plummeted by 110.68% to -2.97 in 2019, then spiked by 283.70% to 0.36 in 2020.
  • Its Equity Ratio stands at 0.36 for Q2 2020, versus -1.56 for Q1 2020 and -2.97 for Q4 2019.